Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AIxCrypto Holdings filings document the completed rebrand from Qualigen Therapeutics and the company’s transition into AI and blockchain-enabled digital infrastructure. Recent Form 8-K disclosures cover operating and financial results, Regulation FD updates, material agreements, and corporate developments related to Real World Asset tokenization, AI agents, Embodied AI infrastructure, and digital-asset strategy.
The filing record also details private-placement financing, common and preferred stock matters, shareholder voting, board and committee governance, and amendments to entrusted investment and securities purchase agreements involving Faraday Future securities. These disclosures show how the company reports capital structure, control relationships, and strategic execution after its business transformation.
Qualigen Therapeutics entered into a private placement on September 19, 2025, under which investors, led by Faraday Future Intelligent Electric Inc., agreed to purchase $41,000,000 of common stock and new Series B convertible preferred stock. Common shares are priced at $2.246 and Series B shares at $1,000 each, with Series B convertible into common at a $2.246 conversion price after required stockholder approval under Nasdaq Rule 5635. The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund current operations, with remaining cash and contributed currency earmarked for cryptocurrency treasury operations.
Univest Securities will receive a 5.5% cash fee on gross proceeds, warrants equal to 6% of securities sold exercisable at $2.47 per share, and up to $150,000 in expense reimbursement. A Lead Investor Agreement gives Faraday Future board representation rights while it owns at least 5% of outstanding common stock, including the appointment of Jiawei Wang as Co‑CEO and Koti Meka as CFO. An advisory firm will receive approximately 60,257 common shares, described as 5% of outstanding common stock following the closing.
Qualigen Therapeutics, Inc. filed an S-1 registration statement seeking to offer additional common stock under the Nasdaq Capital Market ticker QLGN. The document lists a post-offering common share count of 4,909,932 shares assuming all offered shares are sold and shows existing selling stockholders controlling a combined 3,214,292 shares.
The filing discloses recent financing activity: issuance of 32,092 shares to Alpha in lieu of redemption payments at a weighted average price of $14.47 per share; a $550,000 8% convertible debenture to Alpha issued for $500,000 convertible at $30.56 per share with an attached 18,000‑share warrant at $13.00; and a $1,100,000 8% convertible debenture to Chen issued for $1,000,000 convertible at $30.56 with a 36,001‑share warrant at $13.00. Both debentures and warrants include a 9.99 beneficial ownership blocker and purchasers waived certain participation and acceleration rights relating to this offering. The filing also notes Alpha completed conversion of a prior $3,300,000 debenture into 24,379 shares on July 5, 2024.
Qualigen Therapeutics, Inc. filed a current report describing an amendment to its secured borrowing arrangement with Marizyme, Inc. On September 15, 2025, the company entered into Amendment No. 1 to its Amended and Restated Secured Demand Promissory Note dated August 21, 2025.
The amendment corrects the note’s maturity date to August 21, 2026, increases the advance and principal amount by $75,000, and results in a revised outstanding principal balance of $4,526,462.18. The additional advance accrues interest at the same rate set in the existing note, and the company’s obligations remain secured under the existing Security Agreement. The amendment also triggers disclosure of a direct financial obligation under the relevant reporting item.
Qualigen Therapeutics reported that a Nasdaq Hearings Panel has issued a decision on its continued listing. The company previously received an exception to meet Nasdaq’s stockholders’ equity requirement of $2.5 million by July 28, 2025, but its June 30, 2025 Form 10-Q showed stockholders’ equity of approximately negative $1.6 million, so it did not meet the deadline.
The company subsequently closed a private placement of Series A-3 Preferred Stock with net proceeds of about $4.3 million and amended a promissory note with Marizyme, Inc., which increased stockholders’ equity by more than $600,000. The Panel stated that these actions cannot be used to show compliance as of July 28 but granted a final exception to demonstrate compliance in the Form 10-Q for the quarter ending September 30, 2025, which must be filed no later than November 15, 2025. If compliance is not demonstrated then, no additional time will be granted. The company has regained compliance with Nasdaq’s periodic filing rule.
Qualigen Therapeutics has expanded and restructured its lending arrangement with Marizyme through an Amended and Restated Secured Demand Promissory Note with a principal balance of $4,451,462.18. The note carries 18% annual interest, with all principal and interest due in a single balloon payment on August 21, 2026, and the rate rising by 5% upon default.
Qualigen agreed to conditionally forbear from demanding payment for 365 days unless Marizyme defaults, and obtained a security interest in substantially all of Marizyme’s assets. The company also highlights a recent private placement of 4,500 shares of Series A-3 Preferred Stock for approximately $4.5 million in gross proceeds, resulting in net proceeds of $4,257,937.50, and states it believes total shareholders’ equity now exceeds $2.5 million.
Qualigen Therapeutics, Inc. (QLGN) reported a challenging quarter with limited cash and ongoing operating losses. The company had approximately $332,000 in cash and an accumulated deficit of $127.4 million. For the six months ended June 30, 2025 the company used $2.7 million in operating cash and $6.3 million for the year ended December 31, 2024. Loss from continuing operations was $4.33 million for the period versus $3.51 million in the prior comparative period. Short-term borrowings included $3.64 million from nine investors and additional promissory notes totaling $2.3 million. Subsequent to period end, the company closed a private placement in July 2025 raising net proceeds of $4.258 million, which management expects will provide liquidity through year-end. The filing discloses multiple convertible debentures, warrant re-pricings, preferred stock conversions, a 2024 reverse stock split, and a $468,000 loan loss reserve related to Marizyme notes.
Qualigen Therapeutics, Inc. filed a Form D reporting a completed Regulation D offering that raised $4,500,000 in equity securities. The offering consisted of convertible preferred stock that can convert into common shares and was conducted under Rule 506(b). The issuer reports 14 investors and indicates the total offering amount sold equals the offering amount, with $0 remaining to be sold. The company listed no sales commissions or finders' fees (estimated) and stated $0 of gross proceeds will be used for payments to named executive officers or directors (estimate). The issuer declined to disclose revenue/net asset size. The offering was not part of a business combination and the issuer named Univest Securities LLC as the associated broker-dealer.
Alpha Capital Anstalt has filed Amendment No. 2 to Schedule 13G for Qualigen Therapeutics (QLGN).
- Beneficial ownership: 36,434 common shares.
- Ownership percentage: 2.223 % of the 1,635,475 shares outstanding as of 18 Jul 2025.
- Voting & dispositive power: Sole power over all reported shares; no shared power.
- Filer details: Liechtenstein entity, address Altenbach 8, FL-9490 Vaduz.
- Purpose: Certified as a passive investment with no intent to influence control.
The update simply records Alpha Capital’s sub-5 % stake; it carries limited strategic or valuation implications for QLGN shareholders.
On 23 Jul 2025 Qualigen Therapeutics (Nasdaq:QLGN) received a Nasdaq notice that its stockholders’ equity, as reported in the 31 Mar 2025 Form 10-Q, fell below the $2.5 million minimum required by Listing Rule 5550(b)(1). On 24 Jul 2025 Nasdaq’s Office of the General Counsel granted an extension after reviewing the company’s compliance plan and a pro-forma balance sheet reflecting a $4.5 million private placement of Series A-3 preferred stock, which would raise equity above the threshold.
Nasdaq accepted the plan, giving the company up to 12 months to evidence sustained compliance. Management is working to maintain the Nasdaq Capital Market listing but offers no assurance of success. Supporting materials include a press release dated 28 Jul 2025 (Ex. 99.1) and an unaudited pro-forma balance sheet (Ex. 99.2).
On 23 Jul 2025 Qualigen Therapeutics (Nasdaq:QLGN) received a Nasdaq notice that its stockholders’ equity, as reported in the 31 Mar 2025 Form 10-Q, fell below the $2.5 million minimum required by Listing Rule 5550(b)(1). On 24 Jul 2025 Nasdaq’s Office of the General Counsel granted an extension after reviewing the company’s compliance plan and a pro-forma balance sheet reflecting a $4.5 million private placement of Series A-3 preferred stock, which would raise equity above the threshold.
Nasdaq accepted the plan, giving the company up to 12 months to evidence sustained compliance. Management is working to maintain the Nasdaq Capital Market listing but offers no assurance of success. Supporting materials include a press release dated 28 Jul 2025 (Ex. 99.1) and an unaudited pro-forma balance sheet (Ex. 99.2).